Will The FDA Approve This Pfizer Vaccine?

305

  • The companies said they planned to extend the process of submitting data to U.S. regulators for the shot for children.
  • they expect to have three-dose protection data available in early April.
  • Some scientists were critical of this idea, suggesting that regulators should wait for data from a third shot before deciding on the authorization.

As per Wio news in one of their recent articles, the FDA said that it was postponing the advisory panel meeting that was to discuss the authorisation of Pfizer and BioNtech’s covid vaccine for the age group of 6months to 4 years. The suggestions for a three dose vaccine was also made.

The approval

The U.S. Food and Drug Administration on Friday said it was postponing an advisory panel meeting that was to discuss authorization of Pfizer and BioNTech’s COVID-19 vaccine for children 6 months through 4 years of age.

In a separate statement, the companies said they planned to extend the process of submitting data to U.S. regulators for the shot for children under 5.

U.S. regulators have been considering the vaccine for the only age group not yet eligible for the shots, even though the companies said initial results fell short of expectations in 2- to 4-year olds.

Suggesting a three-dose version of the vaccine

In December, Pfizer said it was amending its clinical trial to test a three-dose version of the vaccine because the low dose used generated an immune response in kids aged 2 to 4 that was inferior to the response measured in those aged 16 to 25.

The companies had said they submitted data on the first two doses of what would eventually be a three-dose regimen in the age group at the request of the FDA. On Friday, they said they expect to have three-dose protection data available in early April.

Some scientists were critical of this idea, suggesting that regulators should wait for data from a third shot before deciding on the authorization.

In very young children between 6 months and 2 years old, the vaccine generated an immune response in line with 16- to 25-year-olds, the companies had said.

Did you subscribe to our daily Newsletter?

It’s Free! Click here to Subscribe

Source: Wio News

LEAVE A REPLY

This site uses Akismet to reduce spam. Learn how your comment data is processed.